<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xml:lang="en" article-type="research-article" xmlns:xlink="http://www.w3.org/1999/xlink">
<?release-delay 0|0?>
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">ETM</journal-id>
<journal-title-group>
<journal-title>Experimental and Therapeutic Medicine</journal-title>
</journal-title-group>
<issn pub-type="ppub">1792-0981</issn>
<issn pub-type="epub">1792-1015</issn>
<publisher>
<publisher-name>D.A. Spandidos</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3892/etm.2018.5866</article-id>
<article-id pub-id-type="publisher-id">ETM-0-0-5866</article-id>
<article-categories>
<subj-group>
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>High calcium diet alleviates 5/6 nephrectomy-induced bone deteriorations of lumbar vertebrae in mice</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author"><name><surname>Hou</surname><given-names>Hai-Tao</given-names></name>
<xref rid="af1-etm-0-0-5866" ref-type="aff"/>
<xref rid="fn1-etm-0-0-5866" ref-type="author-notes">&#x002A;</xref></contrib>
<contrib contrib-type="author"><name><surname>Wang</surname><given-names>Ya-Nan</given-names></name>
<xref rid="af1-etm-0-0-5866" ref-type="aff"/>
<xref rid="fn1-etm-0-0-5866" ref-type="author-notes">&#x002A;</xref></contrib>
<contrib contrib-type="author"><name><surname>Shao</surname><given-names>Shi-Ze</given-names></name>
<xref rid="af1-etm-0-0-5866" ref-type="aff"/>
<xref rid="c1-etm-0-0-5866" ref-type="corresp"/></contrib>
<contrib contrib-type="author"><name><surname>Fu</surname><given-names>Song</given-names></name>
<xref rid="af1-etm-0-0-5866" ref-type="aff"/></contrib>
<contrib contrib-type="author"><name><surname>Huang</surname><given-names>Xiang-Peng</given-names></name>
<xref rid="af1-etm-0-0-5866" ref-type="aff"/></contrib>
<contrib contrib-type="author"><name><surname>Wang</surname><given-names>Xiao-Hui</given-names></name>
<xref rid="af1-etm-0-0-5866" ref-type="aff"/></contrib>
</contrib-group>
<aff id="af1-etm-0-0-5866">Department of Spinal and Spinal Cord Surgery, Shandong Wendeng Orthopedic Hospital, Wendeng, Shandong 264400, P.R. China</aff>
<author-notes>
<corresp id="c1-etm-0-0-5866"><italic>Correspondence to</italic>: Dr Shi-Ze Shao, Department of Spinal and Spinal Cord Surgery, Shandong Wendeng Orthopedic Hospital, 1 Fengshan Road, Wendeng, Shandong 264400, P.R. China, E-mail: <email>ss_ze88@163.com</email></corresp>
<fn id="fn1-etm-0-0-5866"><label>&#x002A;</label><p>Contributed equally</p></fn>
</author-notes>
<pub-date pub-type="ppub">
<month>04</month>
<year>2018</year></pub-date>
<pub-date pub-type="epub">
<day>14</day>
<month>02</month>
<year>2018</year></pub-date>
<volume>15</volume>
<issue>4</issue>
<fpage>3483</fpage>
<lpage>3488</lpage>
<history>
<date date-type="received"><day>12</day><month>07</month><year>2017</year></date>
<date date-type="accepted"><day>03</day><month>11</month><year>2017</year></date>
</history>
<permissions>
<copyright-statement>Copyright &#x00A9; 2018, Spandidos Publications</copyright-statement>
<copyright-year>2018</copyright-year>
</permissions>
<abstract>
<p>Dietary calcium (Ca) supplementation has beneficial effects on bone health. However, it is not clear whether a high calcium diet (HCD) following 5/6 nephrectomy (5/6 Nx) is beneficial to bone health. The aim of the present study was to examine the effects of an HCD on bone metabolism using a chronic kidney disease (CKD) mouse model. Male C57BL/6J mice were divided into three groups: Sham group, 5/6 Nx group and 5/6 Nx &#x002B; HCD group. Mice were sacrificed 12 weeks post-surgery. Calcium (Ca) and creatinine (Cr) were measured using standard colorimetric methods and picric acid methods, respectively. Bone metabolism-associated markers, FGF-23, PTH, ALP-b and TRAP-5b were measured using ELISA kits. Lumbar vertebrae histomorphological analysis was performed using hematoxylin and eosin staining. The expression of osteoprotegerin (OPG) and receptor activator of nuclear factor &#x03BA;B ligand (RANKL) mRNA was detected using reverse transcription-quantitative polymerase chain reaction. Impaired renal function and histopathological damage was indicated in 5/6 Nx mice. However, HCD had no significant effects on these changes in 5/6 Nx mice. Notably, mineral metabolism disorder and histopathological damage to lumbar vertebrae were markedly improved in HCD-treated 5/6 Nx mice. Compared with 5/6 Nx mice, HCD supplementation significantly elevated the ratio of OPG/RANKL and inhibited RANKL mRNA expression in lumbar vertebrae. To conclude, the present findings indicated that increased Ca intake is effective in increasing bone mineral content of the lumbar vertebrae in 5/6 Nx mice. These results may provide a basis for the clinical use of dietary Ca supplementation as a therapeutic approach to treat CKD-induced disturbance of mineral metabolism and bone loss.</p>
</abstract>
<kwd-group>
<kwd>high calcium diet</kwd>
<kwd>chronic kidney disease</kwd>
<kwd>bone injury</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>Mineral and bone disorder (MBD) is a common complication associated with chronic kidney disease (CKD) (<xref rid="b1-etm-0-0-5866" ref-type="bibr">1</xref>). CKD-MBD is characterized by severe renal injury-induced mineral and hormone metabolic disorders accompanied by bone deteriorations (<xref rid="b1-etm-0-0-5866" ref-type="bibr">1</xref>). In the progression of CKD, low glomerular filtration rate (GFR) is associated with excessive phosphorus (P) levels, which accelerate osteocyte-derived fibroblast growth factor-23 (FGF-23) and parathyroid hormone (PTH) secretion and adversely affects bone remodeling and resorption, eventually resulting in osteoporotic bone complications (<xref rid="b2-etm-0-0-5866" ref-type="bibr">2</xref>). Previous clinical studies have demonstrated that the severity of CKD is associated with fracture rate (<xref rid="b3-etm-0-0-5866" ref-type="bibr">3</xref>,<xref rid="b4-etm-0-0-5866" ref-type="bibr">4</xref>). Dysregulated mineral homeostasis is a typical feature of CKD (<xref rid="b3-etm-0-0-5866" ref-type="bibr">3</xref>,<xref rid="b4-etm-0-0-5866" ref-type="bibr">4</xref>). Therefore, improving bone mineralization and microstructure in patients with CKD is necessary to reduce the risk of fracture.</p>
<p>Calcium (Ca) is important for bone health. Low Ca intake is associated with an increased risk of osteopenia and bone fractures, whereas high Ca intake has been indicated to protect against osteoporosis (<xref rid="b5-etm-0-0-5866" ref-type="bibr">5</xref>). Epidemiological studies have demonstrated that Ca supplementation has beneficial effects on bone mineral content and bone mineral density (BMD) (<xref rid="b6-etm-0-0-5866" ref-type="bibr">6</xref>,<xref rid="b7-etm-0-0-5866" ref-type="bibr">7</xref>). In rats, Ca supplementation prevented the bone loss and decline in kidney function induced by a high-P diet (<xref rid="b8-etm-0-0-5866" ref-type="bibr">8</xref>). Furthermore, a high calcium diet (HCD) increases bone mineral (Ca and P) content in high-fat diet-induced obese mice (<xref rid="b9-etm-0-0-5866" ref-type="bibr">9</xref>). However, the effects of an HCD on CKD-induced bone have not previously been reported.</p>
<p>Previous studies have employed an 5/6 nephrectomy (5/6 Nx) animal model to evaluate CKD-MBD (<xref rid="b10-etm-0-0-5866" ref-type="bibr">10</xref>,<xref rid="b11-etm-0-0-5866" ref-type="bibr">11</xref>). At 16 weeks following 5/6 Nx, diminished bone microarchitecture was observed in the tibial trabecular bone of cluster of differentiation 1 mice (<xref rid="b11-etm-0-0-5866" ref-type="bibr">11</xref>), which is a well-established mouse model to produce moderate CKD with high-turnover bone injury. In the present study, a CKD-MBD animal model was established in C57BL/6J mice and the effects of an HCD on mineral homeostasis and trabecular bone properties were investigated.</p>
</sec>
<sec sec-type="materials|methods">
<title>Materials and methods</title>
<sec>
<title/>
<sec>
<title>Animal model</title>
<p>The present study was approved by the Ethics Committee of Shandong Wendeng Orthopedic Hospital (Wendeng, China) and was performed in accordance with institutional guidelines. A total of 36 8-week-old male C57BL/6J mice (body weight, 20&#x00B1;2 g) were obtained from Shanghai Laboratory Animal Center (Shanghai, China) and acclimated to the environment for 1 week. Normal dietary Ca (TD.04200, containing 0.6&#x0025; calcium carbonate and 0.4&#x0025; phosphate by weight) and high dietary Ca (TD.96348, containing 2&#x0025; calcium carbonate and 1.25&#x0025; phosphate by weight) were purchased from Harlan Teklad (Madison, WI, USA). The mice individually caged in a temperature-controlled environment (23&#x00B1;2&#x00B0;C; humidity, 60&#x00B1;5&#x0025;) with an artificial 12-h light/dark cycle and were provided with free access to food and tap water. The 5/6 Nx mouse model of CKD was established without angiotensin II infusion according to the method published by Souza <italic>et al</italic> (<xref rid="b12-etm-0-0-5866" ref-type="bibr">12</xref>) and upregulation of blood urea nitrogen and serum creatinine verified successful establishment of the animal model (<xref rid="b12-etm-0-0-5866" ref-type="bibr">12</xref>). The mice were randomly divided into three groups (n=12 in each group): Sham group, sham-operated mice (without removal of kidneys) treated with normal dietary Ca following sham surgery for 12 weeks; 5/6 Nx group, 5/6 Nx mice treated with normal dietary Ca following Nx surgery for 12 weeks; and 5/6 Nx&#x002B;HCD group, 5/6 Nx mice treated with HCD following Nx surgery for 12 weeks. All mice were sacrificed at week 12 via an intraperitoneal injection of sodium pentobarbital (200 mg/kg; Sigma-Aldrich; Merck KGaA, Darmstadt, Germany). Blood was harvested from the heart and centrifuged at 1,500 &#x00D7; g for 15 min at 4&#x00B0;C to obtain serum. Serum (~800 &#x00B5;l), urine (~2 ml) and lumbar vertebrae (L3-L5) tissues were immediately collected and maintained at &#x2212;80&#x00B0;C for further analysis.</p>
</sec>
<sec>
<title>Biochemical markers in serum and urine</title>
<p>The concentrations of Ca (cat. no. C004-3; Nanjing Jiancheng Biology Engineering Institute, Nanjing, China) and creatinine (Cr; cat. no. C011-1; Nanjing Jiancheng Biology Engineering Institute) from the serum and urine were measured using standard colorimetric methods (<xref rid="b13-etm-0-0-5866" ref-type="bibr">13</xref>) and picric acid methods (<xref rid="b14-etm-0-0-5866" ref-type="bibr">14</xref>), respectively. The level of urinary Ca (UCa) was corrected according to the concentration of urinary Cr (UCr). Serum Cr (SCr; cat. no. C011-1; Nanjing Jiancheng Biology Engineering Institute) and blood urea nitrogen (BUN; cat. no. C013-2; Nanjing Jiancheng Biology Engineering Institute) levels were measured using an autoanalyzer and an enzymatic kinetic method with commercial kits following the manufacturer&#x0027;s protocol. Serum levels of FGF-23 (cat. no. 60-6800; Immutopics, Inc., San Clemente, CA, USA), PTH (cat. no. E-EL-M0709c; Elabscience Biotechnology Co., Ltd., Wuhan, China), tartrate resistant acid phosphatase-5b (TRAP-5b; cat. no. SB-TR201A; Immunodiagnostic Systems, Scottsdale, AZ, USA) and alkaline phosphatase (ALP; cat. no. E-EL-M0200c; Elabscience Biotechnology Co., Ltd.) were detected using murine ELISA assays with a SpectraMax M5 ELISA plate reader (Molecular Devices, LLC, Sunnyvale, CA, USA).</p>
</sec>
<sec>
<title>Bone Ca</title>
<p>The lumbar vertebrae were incinerated using a muffle furnace (Thermo Fisher Scientific, Inc., Waltham, MA, USA) at 800&#x00B0;C for 12 h and 10 mg of bone ash was dissolved in 1 ml of 37&#x0025; HCl diluted with Milli-Q<sup>&#x00AE;</sup> water. The calcium content was determined using a kit (cat. no. C004-3; Nanjing Jiancheng Biology Engineering Institute).</p>
</sec>
<sec>
<title>Histomorphology</title>
<p>Kidney tissues were collected immediately following sacrifice and fixed with 4&#x0025; formalin at room temperature for 24 h and paraffin-embedded. Tissues were cut into ~5 &#x00B5;m-thick sections, which were stained with Masson&#x0027;s trichrome (cat. no. SBJ-0290; Nanjing SenBeiJia Biological Technology Co., Ltd., Nanjing, China) as previously described (<xref rid="b15-etm-0-0-5866" ref-type="bibr">15</xref>) and visualized under a microscope (magnification, &#x00D7;200; Leica DM 2500; Leica Microsystems GmbH, Wetzlar, Germany). Renal injury was assessed using a previously described 0&#x2013;4 scale (<xref rid="b16-etm-0-0-5866" ref-type="bibr">16</xref>) as follows: 0, none; 1, &#x003C;10; 2, 10&#x2013;25; 3, 25&#x2013;75; or 4, &#x003E;75&#x0025;.</p>
<p>The lumbar vertebrae were collected immediately following sacrifice and fixed with 4&#x0025; formalin at room temperature for 24 h, and then decalcified in 0.5 M EDTA (pH=8.0) and embedded in paraffin according to standard histological procedures. Sections of ~5 &#x00B5;m were cut and stained with hematoxylin and eosin (H&#x0026;E; cat. no. C0105; Beyotime Institute of Biotechnology,) prior to being visualized under a microscope (magnification, &#x00D7;200; Leica DM 2500).</p>
</sec>
<sec>
<title>Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)</title>
<p>Total RNA from lumbar vertebrae was extracted using TRIzol (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer&#x0027;s protocol. cDNA was synthesized by RT reactions with 2 &#x00B5;g of total RNA using moloney murine leukemia virus reverse transcriptase (Invitrogen; Thermo Fisher Scientific, Inc.) following 37&#x00B0;C for 50 min and 70&#x00B0;C for 15 min. A total of 1 &#x00B5;l cDNA was used for PCR using a DNA Engine (ABI) with SYBR Green PCR Master Mix (Invitrogen; Thermo Fisher Scientific, Inc.). The following thermocycling conditions were applied: 95&#x00B0;C for 10 min followed by 40 cycles of 95&#x00B0;C for 15 sec, 58&#x00B0;C for 30 sec and 72&#x00B0;C for 30 sec. The primers were synthesized by Sangon Biotech Co., Ltd. (Shanghai, China) as follows: osteoprotegerin (OPG), forward 5&#x2032;-GCATTATGACCCAGAAACT-3&#x2032; and reverse 5&#x2032;-ACCTGAGAAGAACCCATC-3&#x2032;; receptor activator of nuclear factor &#x03BA;B ligand (RANKL), forward 5&#x2032;-AACCAAGATGGCTTCTATTACC-3&#x2032; and reverse 5&#x2032;-AAGGGTTGGACACCTGAATG-3&#x2032;; and GAPDH, forward 5&#x2032;-TCACTGCCACCCAGAAGA-3&#x2032; and reverse 5&#x2032;-AAGTCGCAGGAGACAACC-3&#x2032;. Signals were assessed using Quantity One<sup>&#x00AE;</sup> software version 4.5 (Bio Rad Laboratories, Inc., Hercules, CA, USA) and normalized to the GAPDH. Analysis of relative gene expression data used real-time quantitative PCR and the quantitation cycle (Cq) method (<xref rid="b17-etm-0-0-5866" ref-type="bibr">17</xref>).</p>
</sec>
<sec>
<title>Statistical analysis</title>
<p>Data are presented as the mean &#x002B; or &#x00B1; standard deviation as indicated for each group. All statistical analyses were performed using GraphPad Prism software version 5.0 (GraphPad Software, Inc., La Jolla, CA, USA). Inter-group differences were analyzed using one-way analysis of variance with a post hoc Tukey test for multiple comparisons. P&#x003C;0.05 was considered to indicate a statistically significant difference.</p>
</sec>
</sec>
</sec>
<sec sec-type="results">
<title>Results</title>
<sec>
<title/>
<sec>
<title>HCD supplementation has no significant effect on renal dysfunction in 5/6 Nx mice</title>
<p>To evaluate the role of HCD supplementation in 5/6 Nx-induced renal dysfunction, serum levels of SCr and BUN were compared across groups. The levels of SCr and BUN were significantly increased in the 5/6 Nx group compared with the sham-operated group at week 6 and week 12 (P&#x003C;0.05; <xref rid="f1-etm-0-0-5866" ref-type="fig">Fig. 1A and B</xref>); however, HCD supplementation in 5/6 Nx mice did not significantly improve these parameters (<xref rid="f1-etm-0-0-5866" ref-type="fig">Fig. 1A and B</xref>). Masson staining was performed to observe the extent of renal interstitial fibrosis. As indicated in <xref rid="f1-etm-0-0-5866" ref-type="fig">Fig. 1C and D</xref>, increased matrix deposition, interstitial fibrosis and renal lesions were observed in the kidneys from 5/6 Nx mice compared with sham mice, and injury scores were significantly increased (P&#x003C;0.05; <xref rid="f1-etm-0-0-5866" ref-type="fig">Fig. 1D</xref>). Furthermore, HCD supplementation had no marked effect on renal pathological changes in 5/6 Nx mice. These data suggest that the CKD mice models were successfully established and that HCD did not improve renal function in 5/6 Nx mice.</p>
</sec>
<sec>
<title>HCD supplementation regulates bone metabolism-associated biomarkers</title>
<p>Acute kidney injury (AKI) or CKD-induced GFR regression predisposes to bone metabolism disturbances via upregulating serum P (<xref rid="b18-etm-0-0-5866" ref-type="bibr">18</xref>), which accelerates FGF-23 and PTH secretion. Previous studies have demonstrated that increased FGF-23 is associated with CKD or AKI severity (<xref rid="b19-etm-0-0-5866" ref-type="bibr">19</xref>,<xref rid="b20-etm-0-0-5866" ref-type="bibr">20</xref>). FGF-23 is a peptide released from osteocytes and osteoblasts, whilst PTH is associated with Ca, P and FGF-23 levels in CKD (<xref rid="b21-etm-0-0-5866" ref-type="bibr">21</xref>). To evaluate the effect of an HCD in CKD-MBD, the levels of FGF-23 and PTH in the serum of 5/6 Nx mice were measured. Results indicated that serum FGF-23 and PTH levels were significantly increased in the 5/6 Nx group compared with the sham group (P&#x003C;0.05; <xref rid="f2-etm-0-0-5866" ref-type="fig">Fig. 2A and B</xref>). Notably, HCD significantly reversed CKD-induced upregulation of serum FGF-23 and PTH levels in 5/6 Nx mice (P&#x003C;0.05; <xref rid="f2-etm-0-0-5866" ref-type="fig">Fig. 2A and B</xref>). In addition, the effect of 5/6 Nx on markers of bone resorption and formation, ALP and TRAP-5b (<xref rid="b22-etm-0-0-5866" ref-type="bibr">22</xref>,<xref rid="b23-etm-0-0-5866" ref-type="bibr">23</xref>), in the serum of 5/6 Nx mice was assessed (<xref rid="f2-etm-0-0-5866" ref-type="fig">Fig. 2C and D</xref>). 5/6 Nx induced a significant increase in serum TRAP-5b concentration compared with the sham group; however, HCD supplementation significantly decreased TRAP-5b levels in CKD mice (P&#x003C;0.05). No significant difference in ALP concentration was observed in any of the experimental groups.</p>
</sec>
<sec>
<title>HCD supplementation regulates Ca metabolism and bone remodeling</title>
<p>HCD has an important role in the bone-kidney axis and the regulation of calcium homeostasis in CKD (<xref rid="b24-etm-0-0-5866" ref-type="bibr">24</xref>,<xref rid="b25-etm-0-0-5866" ref-type="bibr">25</xref>). The Ca content in serum, urine and bone was measured in CKD mice. Results indicated that 5/6 Nx mice exhibited decreased SCa levels and an ~3-fold increase in UCa excretion compared with the sham group, whereas HCD supplementation significantly increased SCa content and decreased UCa excretion in CKD mice (P&#x003C;0.05; <xref rid="f3-etm-0-0-5866" ref-type="fig">Fig. 3A and B</xref>). At week 12, comparison of the results of bone Ca content between sham and 5/6 Nx groups indicated 5/6 Nx significantly decreased bone Ca content; however, the bone calcium content was significantly increased in 5/6 Nx mice with HCD supplementation (both P&#x003C;0.05; <xref rid="f3-etm-0-0-5866" ref-type="fig">Fig. 3C</xref>). A similar result was obtained for Ca content in the ash of lumbar vertebrae (<xref rid="f3-etm-0-0-5866" ref-type="fig">Fig. 3D</xref>). Furthermore, H&#x0026;E staining was conducted to observe the trabecular bone microstructure of lumbar vertebrae. As indicated in <xref rid="f3-etm-0-0-5866" ref-type="fig">Fig. 3E</xref>, a loss of network connection in the trabecular bone was observed in the 5/6 Nx group compared with the sham group; however, the increased disconnections and separation among trabecular bone network were improved by HCD supplementation in CKD mice.</p>
</sec>
<sec>
<title>HCD supplementation regulates the OPG/RANKL ratio</title>
<p>The maturation and formation of osteoclasts is primarily regulated by the balance of extracellular OPG and RANKL (<xref rid="b26-etm-0-0-5866" ref-type="bibr">26</xref>). OPG and RANKL cytokines affect the activity of osteoblast cells and osteoclastogenesis (<xref rid="b26-etm-0-0-5866" ref-type="bibr">26</xref>). OPG cytokine binds to RANKL and prevents RANKL from binding to the RANK receptor on osteoclast cells, subsequently inhibiting bone resorption and osteoclastogenesis (<xref rid="b27-etm-0-0-5866" ref-type="bibr">27</xref>). Thus, the ratio of OPG/RANKL expression in lumbar vertebrae was determined in the present study (<xref rid="f4-etm-0-0-5866" ref-type="fig">Fig. 4</xref>). RT-qPCR results revealed a significant decrease in the OPG mRNA expression levels and ratio of OPG/RANKL compared with the sham group (P&#x003C;0.05; <xref rid="f4-etm-0-0-5866" ref-type="fig">Fig. 4A, B and D</xref>). Furthermore, RANKL mRNA expression levels were significantly increased in mice treated with 5/6 Nx compared with the sham group (P&#x003C;0.05; <xref rid="f4-etm-0-0-5866" ref-type="fig">Fig. 4A and C</xref>). HCD supplementation significantly reversed the effects of 5/6 Nx on OPG/RANKL and RANKL mRNA expression (P&#x003C;0.05; <xref rid="f4-etm-0-0-5866" ref-type="fig">Fig. 4C and D</xref>). However, no significant difference was observed between the mRNA expression levels of OPG in the 5/6 Nx and 5/6 Nx &#x002B; HCD groups.</p>
</sec>
</sec>
</sec>
<sec sec-type="discussion">
<title>Discussion</title>
<p>Patients with CKD exhibit marked disruptions in bone and mineral metabolism accompanied with biochemical alterations, including elevated FGF-23 and PTH, decreased 1, 25-dihydroxyvitamin D3 (vitamin D3), elevated serum P and decreased SCa (<xref rid="b28-etm-0-0-5866" ref-type="bibr">28</xref>). Oral Ca carbonate affects the positive Ca balance in stage 3 and 4 CKD (<xref rid="b29-etm-0-0-5866" ref-type="bibr">29</xref>). Ca (1,200 mg) combined with vitamin D3 (800 IU) supplementation protects against BMD loss in women with moderate CKD (<xref rid="b30-etm-0-0-5866" ref-type="bibr">30</xref>). Furthermore, dietary Ca supplementation has been indicated to prevent bone loss in several animal models, notably ovariectomized and renal injury rodents (<xref rid="b31-etm-0-0-5866" ref-type="bibr">31</xref>,<xref rid="b32-etm-0-0-5866" ref-type="bibr">32</xref>). These findings suggest that dietary Ca supplementation may serve as an adjunctive therapy for CKD-induced bone loss.</p>
<p>The lumbar vertebra is a hypersensitive site that is susceptible to bone injury (<xref rid="b33-etm-0-0-5866" ref-type="bibr">33</xref>). In clinical practice, kidney transplant recipients have a lower lumbar spine trabecular bone score, which is associated with an increased incidence of fractures (<xref rid="b34-etm-0-0-5866" ref-type="bibr">34</xref>). This suggests that Nx is associated with lumbar vertebrae injury. In the present study, 5/6 Nx significantly decreased SCa content and increased serum PTH and FGF-23 concentration. It is known that PTH stimulates the expression of RANKL, a mediator of osteoclastogenesis and bone resorption (<xref rid="b35-etm-0-0-5866" ref-type="bibr">35</xref>). In the present study, it was observed that RANKL mRNA expression was significantly increased and OPG mRNA expression was decreased in the lumbar vertebrae of 5/6 Nx mice compared with the sham group. These findings indicate that bone resorption and bone loss are enhanced in mice following 5/6 Nx. However, HCD supplementation significantly increased SCa, bone Ca content and Ca/Ash, whilst bone loss of lumbar vertebrae in 5/6 Nx mice was ameliorated. A previous study indicated that dietary Ca supplementation inhibits RANKL-mediated osteoclastic bone resorption via the suppression of PTH (<xref rid="b8-etm-0-0-5866" ref-type="bibr">8</xref>). Thus, these findings suggest that HCD supplementation may increase bone Ca content and bone remodeling via inhibiting RANKL-induced bone resorption in 5/6 Nx mice. Piri <italic>et al</italic> (<xref rid="b36-etm-0-0-5866" ref-type="bibr">36</xref>) assessed the levels of OPG and RANKL associated with dietary supplements of Ca, vitamin D and estrogen, revealing that Ca intake led to an increase in OPG and reduction in RANKL, which ultimately caused an increase in BMD. According to the results of the present study, OPG/RANKL signaling is associated with 5/6 Nx-induced bone deterioration of lumbar vertebrae in mice, which suggests that OPG/RANKL may be an important target for the treatment of CKD-induced bone injury.</p>
<p>FGF-23 is a member of the fibroblast growth factor family and is associated with P homeostasis (<xref rid="b37-etm-0-0-5866" ref-type="bibr">37</xref>). A recent study has revealed that Ca regulates bone FGF-23 expression and that HCD increases serum FGF-23 concentration in Cyp27b1<sup>&#x2212;/&#x2212;</sup> and Gcm2<sup>&#x2212;/&#x2212;</sup> mice (<xref rid="b38-etm-0-0-5866" ref-type="bibr">38</xref>). In parathyroidectomized rats, dietary Ca supplementation increased SCa and FGF-23 concentration (<xref rid="b39-etm-0-0-5866" ref-type="bibr">39</xref>). However, Ca has no effect on FGF-23 promoter activity in cultured osteoblasts (<xref rid="b40-etm-0-0-5866" ref-type="bibr">40</xref>). Furthermore, it has been reported that serum FGF-23 concentration is positively correlated with serum P levels (<xref rid="b41-etm-0-0-5866" ref-type="bibr">41</xref>). In the present study, 5/6 Nx mice had high serum P levels, which was associated with high serum FGF-23 despite hypocalcemia. These data suggest that Ca regulation of FGF-23 expression is also controversial. In the present study, it was identified that dietary Ca supplementation significantly decreased serum P and FGF-23 in CKD mice.</p>
<p>Ca and P are substrates for bone mineralization that are tightly regulated by several hormones, including FGF-23, PTH and vitamin D3 (<xref rid="b42-etm-0-0-5866" ref-type="bibr">42</xref>). Dysregulation of one hormone in this system results in the dysregulation of Ca and P homeostasis; particularly, active vitamin D synthesis is stimulated by hypophosphatemia in the kidney (<xref rid="b42-etm-0-0-5866" ref-type="bibr">42</xref>). FGF-23 is increased in the primary stage of CKD; however, renal tubular injury accelerates FGF23 secretion and results in a decrease in serum vitamin D3 levels, which in turn increases serum phosphate and decreases ionized Ca (<xref rid="b43-etm-0-0-5866" ref-type="bibr">43</xref>). In a clinical setting, foods rich in Ca and low in phosphate are permitted in patients with CKD (<xref rid="b44-etm-0-0-5866" ref-type="bibr">44</xref>). In the present study of 5/6 Nx mice with CKD, serum FGF-23 and PTH were significantly decreased, whereas serum Ca and bone Ca were increased in response to dietary Ca supplementation, ameliorating CKD-induced network connection loss in trabecular bone.</p>
<p>In conclusion, these findings provide a novel insight into the pathophysiological and nutritional role of an HCD in the regulation of Ca homeostasis and bone metabolism-associated hormones in 5/6 Nx mice. In addition, HCD has an anabolic potential to enhance novel bone formation and suppress bone resorption in 5/6 Nx mice. The present study provides the theory base for dietary Ca supplementation beneficial for the balance of bone metabolism in patients with CKD. However, cross-sectional and longitudinal studies are required to elaborate the standards, rules and alimental interaction in routine clinical practice.</p>
</sec>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="b1-etm-0-0-5866"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>F</given-names></name><name><surname>Yin</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Cao</surname><given-names>W</given-names></name></person-group><article-title>Klotho preservation via histone deacetylase inhibition attenuates chronic kidney disease-associated bone injury in mice</article-title><source>Sci Rep</source><volume>7</volume><fpage>46195</fpage><year>2017</year><pub-id pub-id-type="doi">10.1038/srep46195</pub-id><pub-id pub-id-type="pmid">28387374</pub-id></element-citation></ref>
<ref id="b2-etm-0-0-5866"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kochanek</surname><given-names>M</given-names></name><name><surname>Said</surname><given-names>A</given-names></name><name><surname>Lerma</surname><given-names>EV</given-names></name></person-group><article-title>Mineral metabolism in chronic kidney disease</article-title><source>Dis Mon</source><volume>61</volume><fpage>425</fpage><lpage>433</lpage><year>2015</year><pub-id pub-id-type="doi">10.1016/j.disamonth.2015.08.003</pub-id><pub-id pub-id-type="pmid">26518114</pub-id></element-citation></ref>
<ref id="b3-etm-0-0-5866"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naylor</surname><given-names>KL</given-names></name><name><surname>McArthur</surname><given-names>E</given-names></name><name><surname>Leslie</surname><given-names>WD</given-names></name><name><surname>Fraser</surname><given-names>LA</given-names></name><name><surname>Jamal</surname><given-names>SA</given-names></name><name><surname>Cadarette</surname><given-names>SM</given-names></name><name><surname>Pouget</surname><given-names>JG</given-names></name><name><surname>Lok</surname><given-names>CE</given-names></name><name><surname>Hodsman</surname><given-names>AB</given-names></name><name><surname>Adachi</surname><given-names>JD</given-names></name><name><surname>Garg</surname><given-names>AX</given-names></name></person-group><article-title>The three-year incidence of fracture in chronic kidney disease</article-title><source>Kidney Int</source><volume>86</volume><fpage>810</fpage><lpage>818</lpage><year>2014</year><pub-id pub-id-type="doi">10.1038/ki.2013.547</pub-id><pub-id pub-id-type="pmid">24429401</pub-id></element-citation></ref>
<ref id="b4-etm-0-0-5866"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El Desoky</surname><given-names>S</given-names></name><name><surname>Farag</surname><given-names>YM</given-names></name><name><surname>Safdar</surname><given-names>E</given-names></name><name><surname>Shalaby</surname><given-names>MA</given-names></name><name><surname>Singh</surname><given-names>AK</given-names></name><name><surname>Kari</surname><given-names>JA</given-names></name></person-group><article-title>Prevalence of hyperparathyroidism, mineral and bone disorders in children with advanced chronic kidney disease</article-title><source>Indian J Pediatr</source><volume>83</volume><fpage>420</fpage><lpage>425</lpage><year>2016</year><pub-id pub-id-type="doi">10.1007/s12098-015-1986-x</pub-id><pub-id pub-id-type="pmid">26830276</pub-id></element-citation></ref>
<ref id="b5-etm-0-0-5866"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>Q</given-names></name><name><surname>Sergeev</surname><given-names>IN</given-names></name></person-group><article-title>Calcium and vitamin D in obesity</article-title><source>Nutr Res Rev</source><volume>25</volume><fpage>130</fpage><lpage>141</lpage><year>2012</year><pub-id pub-id-type="doi">10.1017/S0954422412000029</pub-id><pub-id pub-id-type="pmid">22588363</pub-id></element-citation></ref>
<ref id="b6-etm-0-0-5866"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnston</surname><given-names>CC</given-names><suffix>Jr</suffix></name><name><surname>Miller</surname><given-names>JZ</given-names></name><name><surname>Slemenda</surname><given-names>CW</given-names></name><name><surname>Reister</surname><given-names>TK</given-names></name><name><surname>Hui</surname><given-names>S</given-names></name><name><surname>Christian</surname><given-names>JC</given-names></name><name><surname>Peacock</surname><given-names>M</given-names></name></person-group><article-title>Calcium supplementation and increases in bone mineral density in children</article-title><source>N Engl J Med</source><volume>327</volume><fpage>82</fpage><lpage>87</lpage><year>1992</year><pub-id pub-id-type="doi">10.1056/NEJM199207093270204</pub-id><pub-id pub-id-type="pmid">1603140</pub-id></element-citation></ref>
<ref id="b7-etm-0-0-5866"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>WT</given-names></name><name><surname>Leung</surname><given-names>SS</given-names></name><name><surname>Wang</surname><given-names>SH</given-names></name><name><surname>Xu</surname><given-names>YC</given-names></name><name><surname>Zeng</surname><given-names>WP</given-names></name><name><surname>Lau</surname><given-names>J</given-names></name><name><surname>Oppenheimer</surname><given-names>SJ</given-names></name><name><surname>Cheng</surname><given-names>JC</given-names></name></person-group><article-title>Double-blind, controlled calcium supplementation and bone mineral accretion in children accustomed to a low-calcium diet</article-title><source>Am J Clin Nutr</source><volume>60</volume><fpage>744</fpage><lpage>750</lpage><year>1994</year><pub-id pub-id-type="doi">10.1093/ajcn/60.5.744</pub-id><pub-id pub-id-type="pmid">7619105</pub-id></element-citation></ref>
<ref id="b8-etm-0-0-5866"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katsumata</surname><given-names>S</given-names></name><name><surname>Matsuzaki</surname><given-names>H</given-names></name><name><surname>Uehara</surname><given-names>M</given-names></name><name><surname>Suzuki</surname><given-names>K</given-names></name></person-group><article-title>Effects of dietary calcium supplementation on bone metabolism, kidney mineral concentrations, and kidney function in rats fed a high-phosphorus diet</article-title><source>J Nutr Sci Vitaminol (Tokyo)</source><volume>61</volume><fpage>195</fpage><lpage>200</lpage><year>2015</year><pub-id pub-id-type="doi">10.3177/jnsv.61.195</pub-id><pub-id pub-id-type="pmid">26052152</pub-id></element-citation></ref>
<ref id="b9-etm-0-0-5866"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>Q</given-names></name><name><surname>Sergeev</surname><given-names>IN</given-names></name></person-group><article-title>High vitamin D and calcium intakes increase bone mineral (Ca and P) content in high-fat diet-induced obese mice</article-title><source>Nutr Res</source><volume>35</volume><fpage>146</fpage><lpage>154</lpage><year>2015</year><pub-id pub-id-type="doi">10.1016/j.nutres.2014.11.003</pub-id><pub-id pub-id-type="pmid">25530010</pub-id></element-citation></ref>
<ref id="b10-etm-0-0-5866"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrari</surname><given-names>GO</given-names></name><name><surname>Ferreira</surname><given-names>JC</given-names></name><name><surname>Cavallari</surname><given-names>RT</given-names></name><name><surname>Neves</surname><given-names>KR</given-names></name><name><surname>dos Reis</surname><given-names>LM</given-names></name><name><surname>Dominguez</surname><given-names>WV</given-names></name><name><surname>Oliveira</surname><given-names>EC</given-names></name><name><surname>Graciolli</surname><given-names>FG</given-names></name><name><surname>Passlick-Deetjen</surname><given-names>J</given-names></name><name><surname>Jorgetti</surname><given-names>V</given-names></name><name><surname>Moys&#x00E9;s</surname><given-names>RM</given-names></name></person-group><article-title>Mineral bone disorder in chronic kidney disease: Head-to-head comparison of the 5/6 nephrectomy and adenine models</article-title><source>BMC Nephrol</source><volume>15</volume><fpage>69</fpage><year>2014</year><pub-id pub-id-type="doi">10.1186/1471-2369-15-69</pub-id><pub-id pub-id-type="pmid">24885705</pub-id></element-citation></ref>
<ref id="b11-etm-0-0-5866"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heveran</surname><given-names>CM</given-names></name><name><surname>Ortega</surname><given-names>AM</given-names></name><name><surname>Cureton</surname><given-names>A</given-names></name><name><surname>Clark</surname><given-names>R</given-names></name><name><surname>Livingston</surname><given-names>EW</given-names></name><name><surname>Bateman</surname><given-names>TA</given-names></name><name><surname>Levi</surname><given-names>M</given-names></name><name><surname>King</surname><given-names>KB</given-names></name><name><surname>Ferguson</surname><given-names>VL</given-names></name></person-group><article-title>Moderate chronic kidney disease impairs bone quality in C57Bl/6J mice</article-title><source>Bone</source><volume>86</volume><fpage>1</fpage><lpage>9</lpage><year>2016</year><pub-id pub-id-type="doi">10.1016/j.bone.2016.02.006</pub-id><pub-id pub-id-type="pmid">26860048</pub-id></element-citation></ref>
<ref id="b12-etm-0-0-5866"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Souza</surname><given-names>AC</given-names></name><name><surname>Tsuji</surname><given-names>T</given-names></name><name><surname>Baranova</surname><given-names>IN</given-names></name><name><surname>Bocharov</surname><given-names>AV</given-names></name><name><surname>Wilkins</surname><given-names>KJ</given-names></name><name><surname>Street</surname><given-names>JM</given-names></name><name><surname>Alvarez-Prats</surname><given-names>A</given-names></name><name><surname>Hu</surname><given-names>X</given-names></name><name><surname>Eggerman</surname><given-names>T</given-names></name><name><surname>Yuen</surname><given-names>PS</given-names></name><name><surname>Star</surname><given-names>RA</given-names></name></person-group><article-title>TLR4 mutant mice are protected from renal fibrosis and chronic kidney disease progression</article-title><source>Physiol Rep</source><volume>3</volume><fpage>e12558</fpage><year>2015</year><pub-id pub-id-type="doi">10.14814/phy2.12558</pub-id><pub-id pub-id-type="pmid">26416975</pub-id></element-citation></ref>
<ref id="b13-etm-0-0-5866"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>L&#x00F6;we</surname> <given-names>A</given-names></name><name><surname>Breuer</surname><given-names>J</given-names></name><name><surname>Palkowitsch</surname><given-names>P</given-names></name></person-group><article-title>Evaluation of the effect of two gadolinium-containing contrast-enhancing agents, gadobutrol and gadoxetate disodium, on colorimetric calcium determinations in serum and plasma</article-title><source>Invest Radiol</source><volume>46</volume><fpage>366</fpage><lpage>369</lpage><year>2011</year><pub-id pub-id-type="doi">10.1097/RLI.0b013e318209ed6f</pub-id><pub-id pub-id-type="pmid">21285889</pub-id></element-citation></ref>
<ref id="b14-etm-0-0-5866"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Massoomi</surname><given-names>F</given-names></name><name><surname>Mathews</surname><given-names>HG</given-names><suffix>III</suffix></name><name><surname>Destache</surname><given-names>CJ</given-names></name></person-group><article-title>Effect of seven fluoroquinolones on the determination of serum creatinine by the picric acid and enzymatic methods</article-title><source>Ann Pharmacother</source><volume>27</volume><fpage>586</fpage><lpage>588</lpage><year>1993</year><pub-id pub-id-type="doi">10.1177/106002809302700512</pub-id><pub-id pub-id-type="pmid">8347910</pub-id></element-citation></ref>
<ref id="b15-etm-0-0-5866"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>D</given-names></name><name><surname>Feng</surname><given-names>J</given-names></name><name><surname>Dai</surname><given-names>C</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Jin</surname><given-names>T</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name></person-group><article-title>Role of peritubular capillary loss and hypoxia in progressive tubulointerstitial fibrosis in a rat model of aristolochic acid nephropathy</article-title><source>Am J Nephrol</source><volume>26</volume><fpage>363</fpage><lpage>371</lpage><year>2006</year><pub-id pub-id-type="doi">10.1159/000094778</pub-id><pub-id pub-id-type="pmid">16873992</pub-id></element-citation></ref>
<ref id="b16-etm-0-0-5866"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>HY</given-names></name><name><surname>Qi</surname><given-names>D</given-names></name><name><surname>Yu</surname><given-names>C</given-names></name><name><surname>Zhao</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>ZK</given-names></name><name><surname>Yang</surname><given-names>MY</given-names></name><name><surname>Zhang</surname><given-names>LM</given-names></name><name><surname>Chen</surname><given-names>DQ</given-names></name><name><surname>Du</surname><given-names>Y</given-names></name></person-group><article-title>Paeonol protects endotoxin-induced acute kidney injury: Potential mechanism of inhibiting TLR4-NF-kappaB signal pathway</article-title><source>Oncotarget</source><volume>7</volume><fpage>39497</fpage><lpage>39510</lpage><year>2016</year><pub-id pub-id-type="doi">10.18632/oncotarget.8347</pub-id><pub-id pub-id-type="pmid">27027358</pub-id></element-citation></ref>
<ref id="b17-etm-0-0-5866"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Livak</surname><given-names>KJ</given-names></name><name><surname>Schmittgen</surname><given-names>TD</given-names></name></person-group><article-title>Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method</article-title><source>Methods</source><volume>25</volume><fpage>402</fpage><lpage>408</lpage><year>2001</year><pub-id pub-id-type="doi">10.1006/meth.2001.1262</pub-id><pub-id pub-id-type="pmid">11846609</pub-id></element-citation></ref>
<ref id="b18-etm-0-0-5866"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kakareko</surname><given-names>K</given-names></name><name><surname>Rydzewska-Rosolowska</surname><given-names>A</given-names></name><name><surname>Brzosko</surname><given-names>S</given-names></name><name><surname>Gozdzikiewicz-Lapinska</surname><given-names>J</given-names></name><name><surname>Koc-Zorawska</surname><given-names>E</given-names></name><name><surname>Samocik</surname><given-names>P</given-names></name><name><surname>Kozlowski</surname><given-names>R</given-names></name><name><surname>Mysliwiec</surname><given-names>M</given-names></name><name><surname>Naumnik</surname><given-names>B</given-names></name><name><surname>Hryszko</surname><given-names>T</given-names></name></person-group><article-title>The effect of nephrectomy on Klotho, FGF-23 and bone metabolism</article-title><source>Int Urol Nephrol</source><volume>49</volume><fpage>681</fpage><lpage>688</lpage><year>2017</year><pub-id pub-id-type="doi">10.1007/s11255-017-1519-9</pub-id><pub-id pub-id-type="pmid">28130714</pub-id></element-citation></ref>
<ref id="b19-etm-0-0-5866"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nitta</surname><given-names>K</given-names></name><name><surname>Nagano</surname><given-names>N</given-names></name><name><surname>Tsuchiya</surname><given-names>K</given-names></name></person-group><article-title>Fibroblast growth factor 23/klotho axis in chronic kidney disease</article-title><source>Nephron Clin Pract</source><volume>128</volume><fpage>1</fpage><lpage>10</lpage><year>2014</year><pub-id pub-id-type="doi">10.1159/000365787</pub-id><pub-id pub-id-type="pmid">25402964</pub-id></element-citation></ref>
<ref id="b20-etm-0-0-5866"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Christov</surname><given-names>M</given-names></name><name><surname>Waikar</surname><given-names>SS</given-names></name><name><surname>Pereira</surname><given-names>RC</given-names></name><name><surname>Havasi</surname><given-names>A</given-names></name><name><surname>Leaf</surname><given-names>DE</given-names></name><name><surname>Goltzman</surname><given-names>D</given-names></name><name><surname>Pajevic</surname><given-names>PD</given-names></name><name><surname>Wolf</surname><given-names>M</given-names></name><name><surname>J&#x00FC;ppner</surname><given-names>H</given-names></name></person-group><article-title>Plasma FGF23 levels increase rapidly after acute kidney injury</article-title><source>Kidney Int</source><volume>84</volume><fpage>776</fpage><lpage>785</lpage><year>2013</year><pub-id pub-id-type="doi">10.1038/ki.2013.150</pub-id><pub-id pub-id-type="pmid">23657144</pub-id></element-citation></ref>
<ref id="b21-etm-0-0-5866"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lavi-Moshayoff</surname><given-names>V</given-names></name><name><surname>Wasserman</surname><given-names>G</given-names></name><name><surname>Meir</surname><given-names>T</given-names></name><name><surname>Silver</surname><given-names>J</given-names></name><name><surname>Naveh-Many</surname><given-names>T</given-names></name></person-group><article-title>PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: A bone parathyroid feedback loop</article-title><source>Am J Physiol Renal Physiol</source><volume>299</volume><fpage>F882</fpage><lpage>F889</lpage><year>2010</year><pub-id pub-id-type="doi">10.1152/ajprenal.00360.2010</pub-id><pub-id pub-id-type="pmid">20685823</pub-id></element-citation></ref>
<ref id="b22-etm-0-0-5866"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Lee</surname><given-names>JW</given-names></name><name><surname>Uy</surname><given-names>L</given-names></name><name><surname>Abosaleem</surname><given-names>B</given-names></name><name><surname>Gunn</surname><given-names>H</given-names></name><name><surname>Ma</surname><given-names>M</given-names></name><name><surname>DeSilva</surname><given-names>B</given-names></name></person-group><article-title>Tartrate-resistant acid phosphatase (TRACP 5b): A biomarker of bone resorption rate in support of drug development: Modification, validation and application of the BoneTRAP kit assay</article-title><source>J Pharm Biomed Anal</source><volume>49</volume><fpage>1203</fpage><lpage>1212</lpage><year>2009</year><pub-id pub-id-type="doi">10.1016/j.jpba.2009.03.002</pub-id><pub-id pub-id-type="pmid">19356879</pub-id></element-citation></ref>
<ref id="b23-etm-0-0-5866"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>An</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>B</given-names></name></person-group><article-title>Natural products for treatment of osteoporosis: The effects and mechanisms on promoting osteoblast-mediated bone formation</article-title><source>Life Sci</source><volume>147</volume><fpage>46</fpage><lpage>58</lpage><year>2016</year><pub-id pub-id-type="doi">10.1016/j.lfs.2016.01.024</pub-id><pub-id pub-id-type="pmid">26796578</pub-id></element-citation></ref>
<ref id="b24-etm-0-0-5866"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haussler</surname><given-names>MR</given-names></name><name><surname>Whitfield</surname><given-names>GK</given-names></name><name><surname>Kaneko</surname><given-names>I</given-names></name><name><surname>Forster</surname><given-names>R</given-names></name><name><surname>Saini</surname><given-names>R</given-names></name><name><surname>Hsieh</surname><given-names>JC</given-names></name><name><surname>Haussler</surname><given-names>CA</given-names></name><name><surname>Jurutka</surname><given-names>PW</given-names></name></person-group><article-title>The role of vitamin D in the FGF23, klotho, and phosphate bone-kidney endocrine axis</article-title><source>Rev Endocr Metab Disord</source><volume>13</volume><fpage>57</fpage><lpage>69</lpage><year>2012</year><pub-id pub-id-type="doi">10.1007/s11154-011-9199-8</pub-id><pub-id pub-id-type="pmid">21932165</pub-id></element-citation></ref>
<ref id="b25-etm-0-0-5866"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>A</given-names></name><name><surname>Quarles</surname><given-names>LD</given-names></name></person-group><article-title>Evidence for FGF23 involvement in a bone-kidney axis regulating bone mineralization and systemic phosphate and vitamin D homeostasis</article-title><source>Adv Exp Med Biol</source><volume>728</volume><fpage>65</fpage><lpage>83</lpage><year>2012</year><pub-id pub-id-type="doi">10.1007/978-1-4614-0887-1_4</pub-id><pub-id pub-id-type="pmid">22396162</pub-id></element-citation></ref>
<ref id="b26-etm-0-0-5866"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pitari</surname><given-names>MR</given-names></name><name><surname>Rossi</surname><given-names>M</given-names></name><name><surname>Amodio</surname><given-names>N</given-names></name><name><surname>Botta</surname><given-names>C</given-names></name><name><surname>Morelli</surname><given-names>E</given-names></name><name><surname>Federico</surname><given-names>C</given-names></name><name><surname>Gull&#x00E0;</surname><given-names>A</given-names></name><name><surname>Caracciolo</surname><given-names>D</given-names></name><name><surname>Di Martino</surname><given-names>MT</given-names></name><name><surname>Arbitrio</surname><given-names>M</given-names></name><etal/></person-group><article-title>Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts</article-title><source>Oncotarget</source><volume>6</volume><fpage>27343</fpage><lpage>27358</lpage><year>2015</year><pub-id pub-id-type="doi">10.18632/oncotarget.4398</pub-id><pub-id pub-id-type="pmid">26160841</pub-id></element-citation></ref>
<ref id="b27-etm-0-0-5866"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walsh</surname><given-names>MC</given-names></name><name><surname>Choi</surname><given-names>Y</given-names></name></person-group><article-title>Biology of the RANKL-RANK-OPG system in immunity, bone, and beyond</article-title><source>Front Immunol</source><volume>5</volume><fpage>511</fpage><year>2014</year><pub-id pub-id-type="doi">10.3389/fimmu.2014.00511</pub-id><pub-id pub-id-type="pmid">25368616</pub-id></element-citation></ref>
<ref id="b28-etm-0-0-5866"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hill Gallant</surname><given-names>KM</given-names></name><name><surname>Spiegel</surname><given-names>DM</given-names></name></person-group><article-title>Calcium balance in chronic kidney disease</article-title><source>Curr Osteoporos Rep</source><volume>15</volume><fpage>214</fpage><lpage>221</lpage><year>2017</year><pub-id pub-id-type="doi">10.1007/s11914-017-0368-x</pub-id><pub-id pub-id-type="pmid">28474258</pub-id></element-citation></ref>
<ref id="b29-etm-0-0-5866"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hill</surname><given-names>KM</given-names></name><name><surname>Martin</surname><given-names>BR</given-names></name><name><surname>Wastney</surname><given-names>ME</given-names></name><name><surname>McCabe</surname><given-names>GP</given-names></name><name><surname>Moe</surname><given-names>SM</given-names></name><name><surname>Weaver</surname><given-names>CM</given-names></name><name><surname>Peacock</surname><given-names>M</given-names></name></person-group><article-title>Oral calcium carbonate affects calcium but not phosphorus balance in stage 3&#x2013;4 chronic kidney disease</article-title><source>Kidney Int</source><volume>83</volume><fpage>959</fpage><lpage>966</lpage><year>2013</year><pub-id pub-id-type="doi">10.1038/ki.2012.403</pub-id><pub-id pub-id-type="pmid">23254903</pub-id></element-citation></ref>
<ref id="b30-etm-0-0-5866"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bosworth</surname><given-names>C</given-names></name><name><surname>de Boer</surname><given-names>IH</given-names></name><name><surname>Targher</surname><given-names>G</given-names></name><name><surname>Kendrick</surname><given-names>J</given-names></name><name><surname>Smits</surname><given-names>G</given-names></name><name><surname>Chonchol</surname><given-names>M</given-names></name></person-group><article-title>The effect of combined calcium and cholecalciferol supplementation on bone mineral density in elderly women with moderate chronic kidney disease</article-title><source>Clin Nephrol</source><volume>77</volume><fpage>358</fpage><lpage>365</lpage><year>2012</year><pub-id pub-id-type="doi">10.5414/CN107180</pub-id><pub-id pub-id-type="pmid">22551881</pub-id></element-citation></ref>
<ref id="b31-etm-0-0-5866"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Charoenphandhu</surname><given-names>N</given-names></name><name><surname>Tudpor</surname><given-names>K</given-names></name><name><surname>Thongchote</surname><given-names>K</given-names></name><name><surname>Saengamnart</surname><given-names>W</given-names></name><name><surname>Puntheeranurak</surname><given-names>S</given-names></name><name><surname>Krishnamra</surname><given-names>N</given-names></name></person-group><article-title>High-calcium diet modulates effects of long-term prolactin exposure on the cortical bone calcium content in ovariectomized rats</article-title><source>Am J Physiol Endocrinol Metab</source><volume>292</volume><fpage>E443</fpage><lpage>E452</lpage><year>2007</year><pub-id pub-id-type="doi">10.1152/ajpendo.00333.2006</pub-id><pub-id pub-id-type="pmid">17003239</pub-id></element-citation></ref>
<ref id="b32-etm-0-0-5866"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fonseca</surname><given-names>D</given-names></name><name><surname>Ward</surname><given-names>WE</given-names></name></person-group><article-title>Daidzein together with high calcium preserve bone mass and biomechanical strength at multiple sites in ovariectomized mice</article-title><source>Bone</source><volume>35</volume><fpage>489</fpage><lpage>497</lpage><year>2004</year><pub-id pub-id-type="doi">10.1016/j.bone.2004.03.031</pub-id><pub-id pub-id-type="pmid">15268901</pub-id></element-citation></ref>
<ref id="b33-etm-0-0-5866"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naitoh</surname><given-names>M</given-names></name><name><surname>Takada</surname><given-names>ST</given-names></name><name><surname>Kurosu</surname><given-names>Y</given-names></name><name><surname>Inagaki</surname><given-names>K</given-names></name><name><surname>Mitani</surname><given-names>A</given-names></name><name><surname>Ariji</surname><given-names>E</given-names></name></person-group><article-title>Relationship between findings of mandibular cortical bone in inferior border and bone mineral densities of lumbar vertebrae in postmenopausal women</article-title><source>Okajimas Folia Anat Jpn</source><volume>91</volume><fpage>49</fpage><lpage>55</lpage><year>2014</year><pub-id pub-id-type="doi">10.2535/ofaj.91.49</pub-id><pub-id pub-id-type="pmid">25797458</pub-id></element-citation></ref>
<ref id="b34-etm-0-0-5866"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naylor</surname><given-names>KL</given-names></name><name><surname>Lix</surname><given-names>LM</given-names></name><name><surname>Hans</surname><given-names>D</given-names></name><name><surname>Garg</surname><given-names>AX</given-names></name><name><surname>Rush</surname><given-names>DN</given-names></name><name><surname>Hodsman</surname><given-names>AB</given-names></name><name><surname>Leslie</surname><given-names>WD</given-names></name></person-group><article-title>Trabecular bone score in kidney transplant recipients</article-title><source>Osteoporos Int</source><volume>27</volume><fpage>1115</fpage><lpage>1121</lpage><year>2016</year><pub-id pub-id-type="doi">10.1007/s00198-015-3424-3</pub-id><pub-id pub-id-type="pmid">26608055</pub-id></element-citation></ref>
<ref id="b35-etm-0-0-5866"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Heerden</surname><given-names>B</given-names></name><name><surname>Kasonga</surname><given-names>A</given-names></name><name><surname>Kruger</surname><given-names>MC</given-names></name><name><surname>Coetzee</surname><given-names>M</given-names></name></person-group><article-title>Palmitoleic acid inhibits RANKL-induced osteoclastogenesis and bone resorption by suppressing NF-kappaB and MAPK signalling pathways</article-title><source>Nutrients</source><volume>9</volume><fpage>E441</fpage><year>2017</year><pub-id pub-id-type="doi">10.3390/nu9050441</pub-id><pub-id pub-id-type="pmid">28452958</pub-id></element-citation></ref>
<ref id="b36-etm-0-0-5866"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piri</surname><given-names>F</given-names></name><name><surname>Khosravi</surname><given-names>A</given-names></name><name><surname>Moayeri</surname><given-names>A</given-names></name><name><surname>Moradipour</surname><given-names>A</given-names></name><name><surname>Derakhshan</surname><given-names>S</given-names></name></person-group><article-title>The effects of dietary supplements of calcium, vitamin D and estrogen hormone on serum levels of OPG and RANKL cytokines and their relationship with increased bone density in Rats</article-title><source>J Clin Diagn Res</source><volume>10</volume><fpage>AF01</fpage><lpage>AF04</lpage><year>2016</year><pub-id pub-id-type="pmid">27790417</pub-id></element-citation></ref>
<ref id="b37-etm-0-0-5866"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stubbs</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Quarles</surname><given-names>LD</given-names></name></person-group><article-title>Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease</article-title><source>Semin Dial</source><volume>20</volume><fpage>302</fpage><lpage>308</lpage><year>2007</year><pub-id pub-id-type="doi">10.1111/j.1525-139X.2007.00308.x</pub-id><pub-id pub-id-type="pmid">17635819</pub-id></element-citation></ref>
<ref id="b38-etm-0-0-5866"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>David</surname><given-names>V</given-names></name><name><surname>Dai</surname><given-names>B</given-names></name><name><surname>Martin</surname><given-names>A</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Han</surname><given-names>X</given-names></name><name><surname>Quarles</surname><given-names>LD</given-names></name></person-group><article-title>Calcium regulates FGF-23 expression in bone</article-title><source>Endocrinology</source><volume>154</volume><fpage>4469</fpage><lpage>4482</lpage><year>2013</year><pub-id pub-id-type="doi">10.1210/en.2013-1627</pub-id><pub-id pub-id-type="pmid">24140714</pub-id></element-citation></ref>
<ref id="b39-etm-0-0-5866"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodriguez-Ortiz</surname><given-names>ME</given-names></name><name><surname>Lopez</surname><given-names>I</given-names></name><name><surname>Mu&#x00F1;oz-Casta&#x00F1;eda</surname> <given-names>JR</given-names></name><name><surname>Martinez-Moreno</surname><given-names>JM</given-names></name><name><surname>Ram&#x00ED;rez</surname> <given-names>AP</given-names></name><name><surname>Pineda</surname><given-names>C</given-names></name><name><surname>Canalejo</surname><given-names>A</given-names></name><name><surname>Jaeger</surname><given-names>P</given-names></name><name><surname>Aguilera-Tejero</surname><given-names>E</given-names></name><name><surname>Rodriguez</surname><given-names>M</given-names></name><etal/></person-group><article-title>Calcium deficiency reduces circulating levels of FGF23</article-title><source>J Am Soc Nephrol</source><volume>23</volume><fpage>1190</fpage><lpage>1197</lpage><year>2012</year><pub-id pub-id-type="doi">10.1681/ASN.2011101006</pub-id><pub-id pub-id-type="pmid">22581996</pub-id></element-citation></ref>
<ref id="b40-etm-0-0-5866"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Tang</surname><given-names>W</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Stubbs</surname><given-names>JR</given-names></name><name><surname>Luo</surname><given-names>Q</given-names></name><name><surname>Pi</surname><given-names>M</given-names></name><name><surname>Quarles</surname><given-names>LD</given-names></name></person-group><article-title>Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D</article-title><source>J Am Soc Nephrol</source><volume>17</volume><fpage>1305</fpage><lpage>1315</lpage><year>2006</year><pub-id pub-id-type="doi">10.1681/ASN.2005111185</pub-id><pub-id pub-id-type="pmid">16597685</pub-id></element-citation></ref>
<ref id="b41-etm-0-0-5866"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imanishi</surname><given-names>Y</given-names></name><name><surname>Inaba</surname><given-names>M</given-names></name><name><surname>Nakatsuka</surname><given-names>K</given-names></name><name><surname>Nagasue</surname><given-names>K</given-names></name><name><surname>Okuno</surname><given-names>S</given-names></name><name><surname>Yoshihara</surname><given-names>A</given-names></name><name><surname>Miura</surname><given-names>M</given-names></name><name><surname>Miyauchi</surname><given-names>A</given-names></name><name><surname>Kobayashi</surname><given-names>K</given-names></name><name><surname>Miki</surname><given-names>T</given-names></name><etal/></person-group><article-title>FGF-23 in patients with end-stage renal disease on hemodialysis</article-title><source>Kidney Int</source><volume>65</volume><fpage>1943</fpage><lpage>1946</lpage><year>2004</year><pub-id pub-id-type="doi">10.1111/j.1523-1755.2004.00604.x</pub-id><pub-id pub-id-type="pmid">15086938</pub-id></element-citation></ref>
<ref id="b42-etm-0-0-5866"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Penido</surname><given-names>MGMG</given-names></name><name><surname>Alon</surname><given-names>US</given-names></name></person-group><article-title>Phosphate homeostasis and its role in bone health</article-title><source>Pediatr Nephrol</source><volume>27</volume><fpage>2039</fpage><lpage>2048</lpage><year>2012</year><pub-id pub-id-type="doi">10.1007/s00467-012-2175-z</pub-id><pub-id pub-id-type="pmid">22552885</pub-id></element-citation></ref>
<ref id="b43-etm-0-0-5866"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nickolas</surname><given-names>TL</given-names></name><name><surname>Jamal</surname><given-names>SA</given-names></name></person-group><article-title>Bone kidney interactions</article-title><source>Rev Endocr Metab Disord</source><volume>16</volume><fpage>157</fpage><lpage>163</lpage><year>2015</year><pub-id pub-id-type="doi">10.1007/s11154-015-9314-3</pub-id><pub-id pub-id-type="pmid">26156535</pub-id></element-citation></ref>
<ref id="b44-etm-0-0-5866"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spiegel</surname><given-names>DM</given-names></name><name><surname>Brady</surname><given-names>K</given-names></name></person-group><article-title>Calcium balance in normal individuals and in patients with chronic kidney disease on low- and high-calcium diets</article-title><source>Kidney Int</source><volume>81</volume><fpage>1116</fpage><lpage>1122</lpage><year>2012</year><pub-id pub-id-type="doi">10.1038/ki.2011.490</pub-id><pub-id pub-id-type="pmid">22297674</pub-id></element-citation></ref>
</ref-list>
</back>
<floats-group>
<fig id="f1-etm-0-0-5866" position="float">
<label>Figure 1.</label>
<caption><p>Changes in renal function in 5/6 Nx mice. (A) SCr and (B) BUN levels in 5/6 Nx mice with or without HCD supplementation were measured. Data are presented as the mean &#x00B1; standard deviation. (C) Masson&#x0027;s trichrome staining was performed in 5/6 Nx mice with or without HCD supplementation to evaluate renal injury (magnification, &#x00D7;200). (D) Kidney injury score for each group. Data are presented as the mean &#x00B1; standard deviation. &#x002A;P&#x003C;0.05 vs. Sham group. 5/6 Nx, 5/6 nephrectomy; SCr, serum creatinine; BUN, blood urea nitrogen; HCD, high calcium diet; ND, not detected.</p></caption>
<graphic xlink:href="etm-15-04-3483-g00.tif"/>
</fig>
<fig id="f2-etm-0-0-5866" position="float">
<label>Figure 2.</label>
<caption><p>HCD supplementation regulates bone metabolism-associated biomarkers. Serum levels of (A) FGF-23, (B) PTH, (C) ALP and (D) TRAP-5b mice were measured in 5/6 Nx with or without HCD supplementation. Data are presented as the mean &#x00B1; standard deviation. &#x002A;P&#x003C;0.05 vs. Sham group; <sup>#</sup>P&#x003C;0.05 vs. 5/6 Nx group. 5/6 Nx, 5/6 nephrectomy; HCD, high calcium diet; FGF-23, fibroblast growth factor-23; PTH, parathyroid hormone; ALP, alkaline phosphatase; TRAP-5b, tartrate resistant acid phosphatase-5b.</p></caption>
<graphic xlink:href="etm-15-04-3483-g01.tif"/>
</fig>
<fig id="f3-etm-0-0-5866" position="float">
<label>Figure 3.</label>
<caption><p>HCD supplementation regulates Ca metabolism and bone remodeling. Concentrations of (A) SCa (B) UCa, (C) bone Ca and (D) Ca/Ash were measured in 5/6 Nx mice with or without HCD supplementation. (E) H&#x0026;E staining (magnification, &#x00D7;200) was performed in 5/6 Nx mice with or without HCD supplementation to evaluate trabecular bone injury. Data are presented as the mean &#x00B1; standard deviation&#x002A;P&#x003C;0.05 vs. Sham group; <sup>#</sup>P&#x003C;0.05 vs. 5/6 Nx group. 5/6 Nx, 5/6 nephrectomy; Ca, calcium; SCa, serum calcium; UCa, urinary Ca; HCD, high calcium diet; H&#x0026;E, hematoxylin &#x0026; eosin.</p></caption>
<graphic xlink:href="etm-15-04-3483-g02.tif"/>
</fig>
<fig id="f4-etm-0-0-5866" position="float">
<label>Figure 4.</label>
<caption><p>HCD supplementation regulated OPG/RANKL ratio. (A) mRNA expression levels of OPG and RANKL were determined. Quantified results of the mRNA expression levels of (B) OPG and (C) RANKL and (D) the ratio of OPG/RANKL were demonstrated in 5/6 Nx mice with or without HCD supplementation. Data are presented as the mean &#x00B1; standard deviation. &#x002A;P&#x003C;0.05 vs. Sham group; <sup>#</sup>P&#x003C;0.05 vs. 5/6 Nx group. OPG/RANKL; osteoprotegerin/receptor activator of nuclear factor kappa B ligand; 5/6 Nx, 5/6 nephrectomy; HCD, high calcium diet.</p></caption>
<graphic xlink:href="etm-15-04-3483-g03.tif"/>
</fig>
</floats-group>
</article>
